SUBSCRIBE
SUBSCRIBE
News   Policy

Amylin Pharmaceuticals, Inc. Says Key Diabetes Drug to Launch this Year

January 28, 2010 | 
1 min read
Bookmark and Share

Reuters -- Amylin Pharmaceuticals Inc said on Wednesday it expects to begin selling the long acting version of its Byetta diabetes drug this year and sees "a clear path to sustained profitability."
Regulatory
MORE ON THIS TOPIC
Health saving account, HSA, financial plan saving for medical expense or medicare cost and benefits concept, doctor with stethoscope standing with huge pink piggy bank or coin bank with medical sign.
Drug pricing
In Affordability Push, EMD Serono Joins TrumpRx While Roche Launches DTC Program
October 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Human resource management and recruitment concept. Job rotation or staff turnover icon.
Government
FDA’s Orphan Drug Director Out Amid IRA Exemption Rollout
October 16, 2025
 · 
2 min read
 · 
Tristan Manalac
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
Gene therapy
FDA’s Second Platform Designation Goes to Krystal After Sarepta Withdrawal
October 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC
October 15, 2025
 · 
1 min read
 · 
Heather McKenzie